Introduction
Owing to a lack of sensitive and specific biomarkers or screening techniques for its early detection, ovarian cancer is typically diagnosed at late stages, when treatment options are limited and often ineffective. Indeed, while a cure rate of 90% can be achieved in women with FIGO (International Federation of Gynecology and Obstetrics) stage I-II disease, this rate can fall to as low as 20% for patients with stage III-IV cancer (Hoskins, 1995) . Unfortunately, only a quarter of ovarian cancer patients are diagnosed as stage I. For this reason, considerable efforts have been devoted to the search of novel ovarian cancer markers but these have not yet been successful.
Many markers such as CA125, CA19.9, CEA, CK19, and HE4 are present at various levels in ovarian cancers, but none of these markers have the required specificity and sensitivity for routine screening of the general population (Mazurek et al., 1998; Hellstrom et al., 2003) . CA125, the best-characterized marker for ovarian cancer, was identified over 20 years ago (Bast et al., 1981) and has been shown to be useful in prognosis, monitoring patients during therapy, and in the detection of recurrence. However, CA125 is also elevated in various benign diseases including endometriosis, ovarian cysts and uterine fibroids, and chronic liver disease (Bast et al., 1998) . In addition, CA125 has been reported to be elevated only in a minority of stage I ovarian cancers (Mann et al., 1988) . There is no evidence for beneficial effects of using CA125 in the routine followup of patients following initial chemotherapy (Berek et al., 1999) . Recently, a method that allows the profiling of proteins in serum using mass spectroscopy (proteomic pattern analysis) was demonstrated to be highly sensitive (100%) and specific (95%) at identifying ovarian cancer in a high-risk population (Petricoin et al., 2002) . Despite this exciting advance, the specificity of this technique is still inadequate for screening of ovarian cancer in the general population, where the vast majority of the cases occur.
New methods that allow large-scale gene expression profiling have allowed an unbiased view of the genes expressed in ovarian cancer (Schummer et al., 1999; Hough et al., 2000; Ismail et al., 2000; Shridhar et al., 2001; Sawiris et al., 2002; Schwartz et al., 2002; Sherman-Baust et al., 2003) . In particular, our serial analysis of gene expression (SAGE) data has been made public (Hough et al., 2000) and has been utilized for various studies of gene expression in ovarian cancer (Hough et al., 2001; Rangel et al., 2003; Yousef et al., 2003) . Interestingly, SAGE allows the identification of novel transcripts that may not be easily identifiable with techniques such as cDNA arrays, which require the availability of known cDNA probes . In a follow up to our ovarian cancer SAGE study, we have used the vast SAGE data available to identify five tags that appeared to be novel and ovarian cancer specific. Upon cloning and sequencing of the corresponding ESTs, we report the identity and initial characterization of human ovarian cancer-specific transcripts 1-5 (HOST1-5). HOSTs are highly upregulated in all ovarian cancer subtypes analysed, but are not generally expressed neither in normal tissues nor in cancers derived from other tissues.
Results

Identification of SAGE tags specifically expressed in ovarian tissues
In order to identify novel ovarian tumor markers, we searched the CGAP SAGE database (www.ncbi.nlm.-nih.gov/SAGE/) for novel tags that were present in ovarian cancer but absent in other neoplastic or normal tissues. At the time of the initial search, the SAGE database contained many ovarian tissue libraries produced by our laboratory (Hough et al., 2000) as well as other libraries submitted by a number of laboratories (Lal et al., 1999; Boon et al., 2002) . We searched for tags that met three conditions: (1) were novel (i.e. did not match a named genbank gene), (2) were expressed at significant levels (42 tags per library) in at least three ovarian cancer libraries, (3) were not expressed in other libraries at high levels (o2 tags per nonovarian cancer library). We identified five tags that met these criteria, and the corresponding genes were named HOSTs (Table 1) .
In order to demonstrate the specificity of HOST expression, 137 SAGE libraries present in the SAGEmap database (as of May 2003) were examined for the presence of these tags. These 137 SAGE libraries represented a vast collection normal and malignant tissues of various origins (Figure 1 ). While the b-actin tag (ACTB1), included as control, was present at high levels in the vast majority of these 137 libraries, very few of these libraries contained HOST tags. Indeed, of the 137 libraries analysed, only eight contained HOST1 tags Figure 1 ). Although sporadic expression could be observed in some nonovarian samples, the bulk of HOST expression was clearly restricted to the ovarian tumors and absent in normal ovarian tissues. Three ovarian cancer cell lines included (ES-2, A2780, and OV1063) did not express HOST genes, but a library consisting of a pool of ovarian cancer cell lines (OVP5) expressed high levels of all the HOST genes, indicating that HOST expression was present in certain ovarian cell lines. We have previously shown that ovarian cancer cell lines may not accurately mimic the gene expression patterns present in the primary ovarian tumors (Hough et al., 2000) .
Identification of the HOST genes
Available ESTs corresponding to the HOST tags were obtained and entirely sequenced. This step allowed the identification of three of the five tags: HOST3 corresponds to CLDN16, HOST4, a proteoglycan link protein (LP) gene, and HOST5, a gene encoding a sodium-dependent phosphate transporter (NaPi), SLC34A2 (Table 1) . While we were sequencing the EST corresponding to HOST1, the CA125 ovarian marker gene was cloned and shown to be a novel mucin, MUC16 (Yin and Lloyd, 2001). Interestingly, HOST1 was found to be identical to MUC16. As CA125 expression and properties have been studied extensively, we did not pursue this candidate any further for this study. Sequencing of the EST corresponding to HOST2 did not reveal homology to any known sequence in genbank.
In an attempt to obtain a full-length transcript of HOST2, we performed 5 0 rapid amplification of cDNA ends (RACE). Sequencing of the RACE product, database searches, and sequence alignments enabled us (a) HOST2 nucleotide sequence. The nucleotide sequence is mostly constituted of Harlequin repeats except for a middle region containing LTR2 repeats (boxed) and a short 3 0 region consisting of a part of a LTR8 repeat (underlined). (b) RNA extracted from normal tissue, cell lines, or primary tumors was electrophoresed and probed using HOST2, 3, 4, or 5 fragments. The lanes corresponded to the following tissue samples: Normal tissues: 1, brain; 2, heart; 3, lung; 4, stomach; 5, liver; 6, colon; 7, kidney; 8, breast; 9, ovary; 10, uterus; 11, placenta; 12, cervix; 13, skeletal muscle; 14, spleen; 15, leukocyte. Cancer cell lines: 1, HT29 (colon); 2, SW480 (colon); 3, ZR-75-1 (breast); 4, MDA-231 (breast); 5, OVCA433 (ovarian); 6, OVCA432 (ovarian); 7, A222 (ovarian); 8, A2780 (ovarian); 9, HeLa (cervical); 10, PC-3 (prostate); 11, 624 MEL (melanoma). Primary tumors: 1, Brain tumor; 2-3, colon tumors; 4-7, ovarian carcinomas; 8, ovarian low malignant potential tumor Characterization of HOSTs by SAGE LBA Rangel et al to obtain the sequence of a putative full-length HOST2 clone (Figure 2a ). Various fragments of HOST2 were present in the database but a full-length clone was not found. Surprisingly, HOST2 sequence did not contain a significant open reading frame. Three different LTRtype elements (Harlequin, LTR2, and LTR8) account for the entire HOST2 transcript. The function of HOST2 is unclear, but it may represent a novel member of the family of noncoding mRNA-like transcripts (Erdmann et al., 2000) .
Validation of HOST expression profiles
To validate the expression profiles discovered using the SAGE databases, Northern analysis was performed and HOST expression was analysed in a variety of normal tissues, cancer cell lines, and primary tumors. Consistent with our previous findings, the expression of the HOST genes was clearly restricted to ovarian tumors and cell lines, and was not typically found in normal tissues (Figure 2b ). HOST2 was expressed in normal uterus, while HOST4 and HOST5 were expressed in normal lung. HOST3 was not found at significant levels in any of the normal tissues evaluated by Northern. Similarly, HOSTs were not expressed in the nonovarian cancer lines studied but each HOST was found to be expressed in at least one ovarian cancer cell line included in the panel. In addition, the HOST genes were also expressed in many primary ovarian tumors included on the blot but were not expressed in the nonovarian tumors included. This was particularly striking for HOST2, which was expressed at significant levels in all the ovarian tumors, including a tumor of low malignant potential. Northern analysis indicated the presence of two different messages of approximately 2 and 3 kb for HOST2 (Figure 2b ). The cDNA that we have identified likely corresponds to the 3 kb product, while the 2 kb product may represent an alternatively spliced version of HOST2. We are currently investigating this possibility.
In order to further characterize HOST expression in ovarian cancer, we performed real-time RT-PCR on a panel of cDNAs generated from microdissected ovarian tumors of various histological subtypes (Hough et al., 2001) . Real-time RT-PCR is much more sensitive than Northern blotting and therefore allows an accurate quantitation of gene expression, even when RNA levels are extremely low. For example, levels of HOSTs undetectable by Northern blotting may still be highly overexpressed compared to levels in normal ovarian surface epithelium (also undetectable by Northern). We found that HOST2, HOST4/LP, and HOST5/SLC34A2 were extremely highly upregulated in serous, clear cell, endometrioid, and mucinous ovarian cancer (Figure 3 ). This level of regulation reflects the fact that HOST mRNAs are extremely low in normal ovarian surface epithelial cells used for comparison. HOST3/CLDN16 was also upregulated, albeit at lower levels ( Figure 3c ). While HOST2, HOST3/CLDN16, and HOST5/ SLC34A2 were elevated to similar levels in all subtypes, HOST4/LP did not appear to be as highly upregulated in serous ovarian carcinomas.
HOST5 expression is associated with increased differentiation
Since we observed that the level of upregulation was variable among the different serous samples studied (see Figure 3) , we investigated whether the expression levels depended on tumor grade (Figure 4) . Interestingly, while HOST2, HOST3/CLDN16, and HOST4/LP expression Figure 3 Real-time RT-PCR analysis of HOST expression in primary ovarian tumor cDNA bank. The y-axis represents the fold overexpression relative to HOSE-B expression. The cDNA bank was constituted by 18 serous (S), six clear cell (CC), six endometrioid (E), and four mucinous (M) ovarian adenocarcinomas. ML3 is an ovarian cystadenoma cell line (C) included as control appeared to be independent of tumor grade, HOST5/ SLC34A2 expression was statistically associated with tumor grade (Po0.01) and more differentiated tumors tended to express higher levels of HOST5/SLC34A2. It is possible that the molecular pathways leading to lowgrade tumors require the expression of SLC34A2. Tumor grade has been associated with outcome and survival (Ozols et al., 1980; Makar et al., 1995; Shimizu et al., 1998) and HOST5 may represent a marker for better prognosis.
Discussion
In this report, we show for the first time that HOST2 (a novel gene), HOST3/CLDN16 (encoding claudin-16), HOST4/LP (encoding a proteoglycan LP), and HOST5/ SLC34A2 (encoding a NaPi cotransporter type IIb) are specifically overexpressed in ovarian cancer. These genes are not ubiquitously expressed in normal tissues and other cancers as demonstrated by our extensive in silico study and validation (Figures 1 and 2 ). These genes may thus represent interesting targets for the diagnosis and therapy of ovarian cancer. It is important to identify and characterize new potential biomarkers for ovarian cancer because of the current lack of sensitive and specific markers. The fact that one of the initial HOST genes, HOST1 was later shown to be MUC16, the gene for the ovarian cancer marker CA125, validates our approach for the identification of tumor markers and suggests that the other HOST genes identified here might indeed represent clinically useful markers. In addition, this approach is easily adaptable to any tumor type present in the SAGE database.
The exact roles of the HOST genes in ovarian cancer are unclear. In addition to providing tumor markers for detection and therapy, these genes may provide new information on the pathways important in ovarian cancer. HOST3/CLDN16 was recently shown to be mutated in familial hypomagnesemia with hypercalciuria and nephrocalcinosis, a recessive condition associated with impaired tubular reabsorption of magnesium and calcium leading to renal failure (Simon et al., 1999) . While claudin-16 was believed to be expressed mostly in the kidney, we now show that its gene is highly overexpressed in ovarian cancer cells. Intriguingly, we have previously shown that claudin-3 and claudin-4 proteins are also upregulated in ovarian cancer . The reasons for the upregulation of multiple claudin genes in ovarian cancer is unclear but may be related to the destruction of functional tight junction through inappropriate expression of claudins, or to junction-related molecular signaling important for the development of this disease. Experiments are currently underway to clarify the role of these various claudins in ovarian cancer.
The HOST4/LP gene is highly homologous to the cartilage link protein gene (CRTL1) and aggrecan (AGC1). The encoded proteins are believed to play a role in the stabilization of the aggregates of proteoglycan monomers with hyaluronic acid in the extracellular cartilage matrix. The role of LP in ovarian cancer is The fold upregulation of each HOST was statistically analysed in regard to the grade of tumors. Using the t-test, we conclude that while HOST5 is more highly expressed in MD/WD when compared to PD, there is no statistically significant association between tumor grade and HOST2, HOST3, or HOST4 expression Characterization of HOSTs by SAGE LBA Rangel et al unclear but may be involved in extracellular matrix (ECM) reorganization in the tumor. We have recently found that ECM reorganization may contribute to drug resistance in ovarian cancer (Sherman-Baust et al., 2003) . In any event, because HOST4/LP encodes a secreted protein, there is possibility that this product may find its way to the bloodstream and represent a target for detection of ovarian cancer. Further experiments will be necessary to test this hypothesis. HOST5/ SLC34A2 encodes a member of the type II NaPi transporter family. These transporters are generally important for inorganic phosphate reabsorption in the renal tubule and absorption in the small intestine and are thus crucial in the maintenance of phosphate homeostasis (Murer et al., 2000) . Consistent with our findings (Figures 1 and 2) , these transporters have also been found expressed in lung (Hashimoto et al., 2000) . Here, we show that HOST5/SLC34A2 is highly overexpressed in ovarian cancer. Furthermore, overexpression of HOST5/SLC34A2 correlated with differentiation of ovarian tumors: although overexpressed in poorly differentiated tumors, the levels of upregulation are much higher in moderately to well-differentiated tumors. It is unclear whether SLC34A2 is involved in the process of differentiation in ovarian cancer, but it is interesting that type II transporters have been implicated in the differentiation of pancreatic cells (Mashima et al., 2001) and are highly expressed in CaCo-2, a colon cancer cell line known for its differentiated phenotype where active transport would be expected.
Finally and perhaps most intriguingly is our discovery of HOST2 expression in ovarian cancer. HOST2 does not appear to have an ORF and may represent a noncoding RNA-like transcript. There is a growing family of nontranslatable, mRNA-like molecules, which have been implicated in the regulation of gene expression (Erdmann et al., 2000) . H19 probably represents the best-studied untranslated RNA. However, the exact role of H19 remains controversial, as both tumor suppressive and oncogenic roles have been assigned to this transcript (Hao et al., 1993; Steenman et al., 1994; Lottin et al., 2002) . In this study, we show that HOST2 is expressed at extremely high levels in every ovarian tumors studied (see Figures 1 and 2 ) and is also elevated in normal uterus. It will be extremely interesting to determine the role of this unusual transcript in ovarian cancer.
In summary, this report describes four genes implicated for the first time in ovarian tumorigenesis. Although the function of these genes in ovarian tumor initiation and progression is unclear, it is interesting that three of these genes represent membrane or secreted proteins and may thus represent useful new markers for detection and/or treatment of this disease.
Materials and methods
HOST identification and in silico analysis
Ovarian cancer SAGE libraries construction, sequencing, and analysis have been reported (Hough et al., 2000) . During the analysis of our ovarian expression databases, we identified five ovarian cancer-specific tags that did not match known cDNAs and we named those tags as (HOSTs) ( Table 1) . HOST tags were shown to be mostly ovarian specific through analysis of the ncbi SAGEmap database (Lal et al., 1999) (http:// www.ncbi.nlm.nih.gov/SAGE/). A total of 137 SAGE libraries (all those containing over 10 000 tags) were downloaded and included in the analysis. These libraries represented a wide variety of normal and cancer tissues. For normalization purposes, expression levels for each of the libraries were converted to tags per million for these analyses. Graphical representation of expression profiles for b-actin (control) and HOST1-5 were generated for all 137 libraries using the Treeview software (Eisen et al., 1998) .
Sequencing and 5
0 RACE ESTs corresponding to the HOST tags were obtained from Research Genetics (Carlsbad, CA, USA), and sequenced using the Thermo Sequenase Radiolabeled Terminator Cycle Sequencing kit (USB Corporation, Cleveland, OH, USA) according to the manufacturer's specifications. EST I.M.A.G.E. number 2289411, 2457399, 2293979, and 2207825 corresponded to HOST2, 3, 4, and 5, respectively. Except for HOST2, EST sequencing allowed the identification of the transcripts using the current GenBank database. RACE technique was used to obtain the 5 0 -end of HOST2 using the Marathont cDNA Amplification kit (Clontech Laboratories, Inc., Palo Alto, CA, USA). Briefly, poly(A) RNA was extracted from a primary ovarian tumor, and cDNA was synthesized with the Marathont cDNA Primer that anchors at base poly(A) tail. Ovarian cancer cDNA was ligated to the Marathont cDNA adaptor. 5 0 RACE PCR was performed using the Marathont adaptor primer 1, which anchors to the adaptor-ligated cDNA, and an antisense gene specific primer (5 0 -CAGGGAACCAAGAAATGTAGCAG-3 0 ), designed to cross LTR2/ERV1 and Harlequin/ERV1 repeat sequences in HOST2. The PCR cycling conditions were: 951C, 1 min; 541C, 1 min 30 s; 701C, 4 min; 40 cycles. PCR products were sequenced as described above.
RNAs and Northern blotting
RNA for cancer cell lines and primary tumors was prepared as previously described or purchased from Geneka Biotechnology Inc. (Montreal, Canada). RNA from normal tissue was purchased from Invitrogen (Carlsbad, CA, USA). RNA from ovarian and colon tumors have been described (Sawiris et al., 2002) . Ovarian cystadenoma line ML-10 (Luo et al., 1997) and ovarian surface epithelial line HOSE-B (Gregoire et al., 1998) were used as control. Total RNA (10 mg) was electrophoresed on 1% agarose/12.5% formaldehyde gels, transferred by capillarity onto nylon membranes, and crosslinked by UV irradiation and by incubation of the membranes at 801C for 2 min. Blots were prehybridized and hybridized with DNA probes at 651C in hybridization solution containing 1% BSA, 7% SDS, 0.25 m phosphate buffer, and 1 mm EDTA. Following hybridization, blots were washed six times under high stringency conditions (40 mm phosphate buffer, 1% SDS at 651C) and exposed to a PhosphorImager screen for 24 h. HOST probes were obtained by isolating restriction fragments from corresponding ESTs (see above) and were labeled with [a 32 P]dATP by randomprimed labeling (Roche Molecular Biochemicals, Indianapolis, IN, USA). Northern blot membranes were photographed under UV light to verify loading.
Real-time RT-PCR
Total RNA (1 mg) from the various tissues and cell lines, including a panel of microdissected tumors of various histological subtypes (Hough et al., 2001) , was used to generate cDNA using the Taqman Reverse Transcription Reagents (PE Applied Biosystems, Foster City, CA, USA). The GeneAmp 5700 Sequence Detection System (PE Applied Biosystems) was used for detecting real-time RT-PCR products with the SYBR Green I assay, as previously described (Hough et al., 2001 ). The primers for HOST genes and the control GAPDH were designed to cross intron-exon boundaries to distinguish PCR products generated from genomic versus cDNA template. As we could not identify intron-exon boundaries in the HOST2 sequence, real-time RT-PCR was performed by the poly(A) cDNA-specific RT-PCR method (Folz and Nepluev, 2000) . The primer sequences are available from the authors.
Each PCR reaction was optimized to ensure that a single band of the appropriate size was amplified and that no bands corresponding to genomic DNA amplification or primer-dimer pairs were present. The PCR cycling conditions were performed for all samples as follows: 501C, 2 min for AmpErase UNG incubation, 951C, 10 min for AmpliTaq Gold activation, and 40 cycles for the melting (951C, 15 s) and annealing/extension (601C for 1 min) steps. PCR reactions for each template were done in duplicate in 96-well plates.
The comparative C T method (PE Applied Biosystems, Foster City, CA, USA) was used to determine relative quantitation of gene expression for each gene compared to the GAPDH control. First, the CT values from GAPDH reactions were averaged for each duplicate. Next, the relative difference between GAPDH and each duplicate was calculated. This value was then averaged for each duplicate set and normalized to the value obtained for HOSE-B to determine the relative fold overexpression for each sample relative to this nonmalignant ovarian surface epithelial cell culture. The t-test was used to determine the significance of differences in gene expression levels in the various samples.
Abbreviations RT-PCR, reverse transcription-PCR; SAGE, serial analysis of gene expression; HOST, human ovarian-specific transcript; NaPi transporter, sodium-dependent phosphate transporter.
